What is Rxsight?
RxSight enables doctors and patients to predictably optimize vision after cataract surgery through an office-based IOL enhancement. Founded in 1997 and headquartered in California, RxSight has developed proprietary technology that allows for post-operative adjustment of intraocular lenses (IOLs), offering a level of customization previously unavailable. This innovation addresses a critical need in the ophthalmic market for improved patient satisfaction and visual acuity following refractive lens exchange procedures. The company's unique approach positions it as a leader in advanced vision correction solutions.
How much funding has Rxsight raised?
Rxsight has raised a total of $317.8M across 7 funding rounds:
Private Equity
$8.5M
Private Equity
$12.7M
Debt
$17M
Private Equity
$52M
Private Equity
$50M
Debt
$60M
Share Placement
$117.6M
Private Equity (2009): $8.5M, investors not publicly disclosed
Private Equity (2011): $12.7M, investors not publicly disclosed
Debt (2015): $17M, investors not publicly disclosed
Private Equity (2015): $52M featuring H.I.G. BioVentures, Longitude Capital, Balance Point Capital, and RA Capital Management
Private Equity (2017): $50M, investors not publicly disclosed
Debt (2020): $60M with participation from Oxford Finance
Share Placement (2021): $117.6M, investors not publicly disclosed
Key Investors in Rxsight
Oxford Finance
Oxford Finance, founded in 2002 and headquartered in Alexandria, Virginia, is a specialty finance firm that offers flexible financial solutions to healthcare and life sciences companies worldwide, indicating a focus on debt financing for established companies.
H.I.G. BioVentures
H.I.G. BioVentures, part of H.I.G. Capital, is a venture capital firm specializing in the healthcare and life sciences sectors, likely providing growth equity to companies with strong technological potential.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on public and private healthcare and life science companies, including those developing drugs, medical devices, and diagnostics, suggesting a strategic interest in innovative medical technologies.
What's next for Rxsight?
With the recent major strategic investment and substantial overall capital secured, Rxsight is poised for significant scaling and market penetration. The enterprise-level funding suggests a focus on expanding commercial operations, further research and development into next-generation vision enhancement technologies, and potentially broadening its global reach. This strategic backing will likely enable RxSight to solidify its position in the competitive ophthalmic device market, driving innovation and improving patient care worldwide. The company's trajectory indicates a strong future in enhancing post-surgical visual outcomes.
See full Rxsight company page
